Fattyloid

Fattyloid is a South Korean biotechnology company focused on developing first-in-class therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company's core technology centers on the Fattyloid concept, which involves the interaction between specific fatty acids and amyloid proteins to promote the clearance of neurotoxic aggregates. Their lead candidate, FL-101, is a small molecule designed to cross the blood-brain barrier and reduce amyloid-beta plaques. Fattyloid aims to address the high unmet medical need in dementia by targeting lipid-mediated protein degradation pathways. The company was founded in 2020 and is headquartered in Seoul.